Tysabri News
Timothy L. Vollmer, MD
Professor

Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center
My Educational Video on MS and MS Trials
Produced by www.MSNewsChannel.com
Jennifer
Landry

News Editor
Josi
Creek

News Editor
Desinie
Smith

Senior News Editor
Patti
McArthur

News Editor
Erin
Tysabri
Editor
We Accept No Advertising
  • Founded 2004 by Stan Swartz

  • This site is run by Facebook Volunteers.

    Visit our Facebook Page at:

    facebook.com/StansAngels


    400,000+ Facebook & MySpace Visitors! MS News Channel Visitors:
    HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
    CLICKING ON THE RED BUTTON BELOW
    You'll get FREE Breaking News Alerts on new MS treatments as they are approved
    PLUS: We will notify you when we produce videos like the one below that we filmed with Dr. Timothy Vollmer to help you understand Tysabri's temporary withdrawal from the market
    Timothy L. Vollmer M.D.
    Department of Neurology
    University of Colorado Health Sciences Center
    Co-Director of the RMMSC at Anschutz Medical Center
    and
    Medical Director-Rocky Mountain MS Center


    Click to view 1280 MS Walk photos!

    "MS Can Not
    Rob You of Joy"
    "I'm an M.D....my Mom has MS and we have a message for everyone."
    - Jennifer Hartmark-Hill MD
    Beverly Dean

    "I've had MS for 2 years...this is the most important advice you'll ever hear."
    "This is how I give myself a painless injection."
    Heather Johnson

    "A helpful tip for newly diagnosed MS patients."
    "Important advice on choosing MS medication "
    Joyce Moore

    Previious Posts

    MS NEWS ARCHIVES: by week

    This page is powered by Blogger. Isn't yours?

    Wednesday, November 8

     
    Elan Extends Tysabri's Reach to Canada [more]
    ...To put this in perspective, Canada has possibly the highest rate of MS in the whole world. An estimated 55,000 to 75,000 Canadians suffer from the disease -- that's nearly one-fifth the estimated number of patients in the United States.

    The fortunes of Elan will rise and fall with the prospects of Tysabri. When the drug was taken off the market early last year, many investors pegged the company for bankruptcy because of its high debt load. Now that the drug has been approved for sale again in the U.S. and also for marketing in the EU, Elan has a chance to start making enough money to stem the company's losses and hopefully begin paring down some of the nearly $2 billion in debt that will be due in varying amounts in 2008 and 2011.....